Cetuximab in combination with either sequential gemcitabine followed by docetaxel or with a combination of carboplatin and gemcitabine in chemonaive patients with advanced non-small cell lung cancer (NSCLC): Preliminary toxicity profile from the ongoing phase II/III GemTax IV trial